Abstract: Background/objective: The World Health Organization (WHO) recommends routine assessment of antiretroviral treatment outcomes to detect treatment failure early and prevent the development of drug resistance. The aim of this study was to describe treatment outcomes of antiretroviral therapy (ART) over 2 years in children living with the human immune deficiency virus enrolled in the paediatric HIV clinic at the Lagos University Teaching Hospital (LUTH).

Materials and methods: This was a retrospective study of antiretroviral treatment outcomes in 278 children receiving antiretroviral therapy at the paediatric HIV clinic of LUTH. Demographic, clinical and laboratory data were retrospectively collected from clinical records of pediatric patients who received antiretroviral therapy for 2 years (from November 2015 to December 2017). Virological failure was defined as viral load > 400 copies/ml and immunological failure was defined as a CD4 count <100 cells/mm$^3$ or CD4 % <15% after receiving antiretroviral agents for 12 months. Data was analysed using graph pad prism version 5.0.

Results: After 12 months on antiretroviral therapy (ART), 101 (36%) had virological failure while 14 (5%) and 36 (13%) failed immunologically [CD4 count <100 cells/mm$^3$ and CD4 <15% respectively]. Virological blips were observed at 24 months in 6.1% of patients while immunovirological discordance occurred in 30% of patients (poor virological clearance despite good immunological recovery). High baseline viral load (>5000 copies/ml), poor adherence (<95%) and low baseline CD4 counts (101-249 cells/mm$^3$) were significantly associated with virological failure, while low baseline CD4 counts (<350 cells/mm$^3$) and poor adherence (<95%) were significantly associated with immunologic failure.

Conclusion: The treatment outcomes observed in this study are similar to those reported in earlier studies. At 1 and 2 years of antiretroviral therapy, there was immune restoration however 101 (36%) and 87 (31%) respectively had virological failure despite good adherence to therapy and good Immunological restoration. This calls for early initiation and switch to second and third line drugs.

Key words: Human immunodeficiency virus (HIV), zidovudine, lamivudine, nevirapine, virological blips, immunovirological discordance, children, Nigeria.
therapeutic success or failure. Delayed detection of treatment failure leads to poor treatment outcomes and may increase drug toxicity, cause accumulation of drug resistance associated mutations and may result in increased morbidity and mortality. This makes regular monitoring of children on antiretroviral therapy an important activity to optimize treatments and prevent treatment failure and eventual emergence of HIV drug resistance.

In Nigeria good ART outcomes have been reported from paediatric HIV/AIDS programs, comparable to those in high-income countries. Some of these studies consisted of different designs with varying sample sizes and data on patient characteristics, adherence and treatment outcomes in adults and children. This study assessed and described the treatment outcomes in children aged 2-14 years living with human immune deficiency virus (HIV) and receiving antiretroviral drugs for 2 years in Lagos, Nigeria.

Methods

The study was done at the paediatric HIV clinic of the Lagos University Teaching Hospital (LUTH), Lagos, Nigeria. The study population comprised of paediatric patients living with HIV, aged 2 years to 14 years and receiving a combination of zidovudine, lamivudine and nevirapine for a period of two years from November 2015 to December 2017. In this observational study all patients were included into this study as they consecutively attended the clinic. Diagnosis and confirmation of HIV status, choice and initiation of 1st line ARV therapy were already decided by the HIV treatment Program team before the study according to the National guidelines.

Standardized data collection forms were used to document demographic, clinical and laboratory data including anthropometric measurements, viral load, CD4 count, CD4 %, haematological and biochemical parameters. Virological and immunological outcomes were assessed. Virological failure (VF) was defined as a HIV RNA level of equal or more than 400 copies/ml at the 1 year visit after initiation of antiretrovirals in line with local laboratory assay detection limits at the time of study. Virological suppression was defined as VL<400 cps/μl. Immunological failure was defined according to the WHO guidelines as having a CD4 T lymphocytes count of less than 100 cells/mm³ or CD4% < 15% at twelve months post ART. Immune recovery was defined as CD4% ≥25% after one year of ART. Adherence was assessed by refill visit report for picking up medications from the pharmacy on the appointment day. Refill adherence was calculated based on the cumulative sum of days that a patient was late for ART pick-up appointments, divided by the total number of days over all such periods. Each refill period was identified as the interval between the last pharmacy visit date and the schedule refill date. Refill adherence was 100% if all pills during the schedule refill period were picked up on time. Good adherence and poor adherence was defined using a threshold of > 95% and <95% respectively.

Ethics approval

Ethical approval was received from the Lagos University Teaching Hospital Health Research Ethics Committee (ADM/DCST/HERC/2259) and the permission to collect data was granted by the Director of LUTH HIV clinic. Informed consent for participation in the study was obtained from children’s parent/caregivers, next of kin, caretakers, or guardians on behalf of the minors/children who participated. The names of the patients and their unique antiretroviral treatment numbers were not included during data collection to protect patient identity.

Statistical analysis

Data for continuous variables were expressed as mean and standard deviation (SD) if normal distributed or median and inter-quartile range (IQR) if not normally distributed. Categorical data were reported as counts and percentages. Analysis was conducted using Graph Pad Prism version 5 for windows (Graph Pad Software, San Diego California USA.. In comparative analyses, the Chi-square test was used to investigate the association between categorical covariates and outcomes. Parameters associated with virological or immunological failure, according to the univariate analysis, were entered into a linear regression model to determine the respective contribution of each patient characteristics predicting virological or immunological failure. The association was measured by adjusted odds ratio (AOR). Factors with P-value 0.2 or less at bivariate analysis were selected for further multivariate analysis.

Results

Study population

A total of 278 children were enrolled in this study, comprising one hundred and forty two (51%) females and one hundred and thirty six (49%) males. The median age at treatment initiation was 8 years (IQR 4.6-14.0). Table 1 shows patient characteristics. The patients received combination antiretroviral therapy with body weight based dosing. At antiretroviral initiation and 2 years two hundred and fifty six patients (92.1%) and one hundred ninety five 195(70%) respectively received fixed dose combination of zidovudine, lamivudine and nevirapine. Patients in whom first line therapy failed or were not tolerated received second line drugs. Some patients were switched to protease inhibitors or efavirenz containing regimens if they were on treatment for tuberculosis with rifampicin containing regimens. Table 2 shows antiretroviral first line regimens (initial and at 2 years).
The mean cumulative percentage adherence to drug-refill visits was 100±12.44. In the 1st years, 75(27%) had poor adherence (<95%) while 203(73%) had good adherence (>95%) while in the 2nd year we had <95% 52(19%) and >95% 226(81%) respectively. Poor adherence (<95%) to drug refill visits (adjusted OR [AOR] 1.51; 95% CI: 1.20-3.01) was significantly associated with virologic failure. Also poor adherence to drug refill (95%) was significantly associated with immunological failure (CD4 count <100 cells/mm³).

**Immunovirological response**

The viral loads at 6, 12, 18 and 24 months are significantly different from baseline counts (Table 3). There was therefore a decrease in the proportion of patients with virological failure as treatment progressed. After 12 months on antiretroviral therapy, 101(36%) had failed virologically (viral load > 400 copies/ml). One hundred and seventy seven patients (64%) achieved viral suppression (viral load > 400 copies/ml) at 12 months. However at 2 years (24 months) 17 patients (6.1%) who had been viral suppressed at 18 months had a viral blip at 24 months (VL > 500 copies/ml). Table 3 also shows mean CD4 count, percentages, gain, immunological failure and recovery over time from baseline to 24 months. Discordant immunovirological responses following ART initiation occurred in 30% of patients at 2 years and was associated with baseline CD4 cell count <500, vi > 1000 and adherence <95%. At 2 years, the median CD4 count was 826 cells/mm³ and the median CD4 count was 29%. 10(4%) patients had CD4 <100cells/mm³, 38(14%) had CD4 <15% while 87 (31%) had VL/mm³ >400copies/ml. Virolige response lagged behind Immunological response.

Viral blips were commoner in patients with low adherence (Table 4), After 12 months on antiretroviral therapy, 14% of patients and 36(13%) failed immunologically (CD4 count <100cells/mm³ and CD4%, 15% respectively). Tables 5, 6 and 7 show factors associated with virological and immunological failure. On multivariate analysis factors significantly associated with virological failure were baseline viral load >500 copies/ml (AOR 7.476; 95% CI 2.34-10.050) p=0.001, baseline CD4 count 101-249 cells/mm³ (advanced immunosuppression) (adjusted OR [AOR] 0.215; 95% CI: 0.064-0.727), p-value (0.013) and poor adherence (<95%) (Adjusted OR [AOR] 1.51; 95% CI: 1.20-3.01) (p<001).

Low baseline CD4 counts (<350 cells/mm³) and poor adherence to drug refill (95%) were significantly associated with immunological failure (CD4 count <100 cells/ml) pre-initiation CD4 count 50-100mm³ (severe immunosuppression) was significantly associated with immunological failure (CD4 <15%) at 1 year.
Table 3: Immunovirological responses at baseline and after 6, 12, 18 and 24 months of antiretroviral therapy

| Viral load (VL) (copies/ml) | baseline | 6 months* | 12 months* | 18 months* | 24 months* |
|----------------------------|----------|-----------|------------|------------|------------|
| Mean viral load            | 13070±94±28 | 54268±155 | 38268±126 | 30040±105 | 52376±34  |
| Proportion of children with viral load <400 | 87(31%) | 160(58%) | 177(64%) | 186(67%) | 191(69%)  |
| Proportion of children with viral load >400 | 191(69%) | 118(42%) | 101(36%) | 93(33%) | 87(31%)  |
| P-value                     | P<0.0001* | P<0.0001* | P<0.0001* | P<0.0001* | P<0.0001* |

**Immunological parameters**

| Mean CD4+ cells/mm³ | 902±652 | 953±692 | 1028±686 | 1070±722 | 1000±28  |
| Mean CD4%           | 35.8±20 | 34.4±19 | 35±19 | 36±19 | 34±19  |
| Mean CD4+ cells gain after ARV | 52(5%) | 126(14%) | 168(19%) | 98(11%) |
| Proportion of children with CD4 cells <100/mm³ | 14(5%) | 15(5%) | 14(5%) | 9(3%) | 10(4%)  |
| Proportion of children with CD4% <15% | 48(17%) | 47(17%) | 36(13%) | 38(14%) | 38(14%)  |
| Proportion of children with CD4% <25% | 172(62%) | 179(64%) | 192(69%) | 188(68%) | 177(64%)  |

*P value < 0.05 is statistically significant

Table 4: Factors associated with virologic blips at 24 months of antiretroviral therapy

| Characteristics | Viral Blip No (%) | Viral Blip No (%) | X² | P-value |
|----------------|------------------|------------------|----|---------|
| Age Group      |                  |                  |    |         |
| 2-9 years      | 6(5)             | 136(95)          | 0.447 | 0.801  |
| 10-14 years    | 8(7)             | 128(93)          |     |         |
| Gender         |                  |                  |    |         |
| Male           | 9(7)             | 128(93)          | 0.097 | 0.755  |
| Female         | 8(6)             | 133(94)          |     |         |
| Weight (kg)    |                  |                  |    |         |
| ≤25kg          | 12(6)            | 190(94)          | 0.039 | 0.843  |
| >25kg          | 5(7)             | 71(93)           |     |         |
| Adherence      |                  |                  |    |         |
| ≤95%           | 6(10)            | 52(90)           | 2.284 | 0.131  |
| >95%           | 11(15)           | 209(95)          |     |         |

Virologic Blips is higher among subjects with adherence <95%

Table 5: Factors associated with virological failure (VL>400 copies/ml) at one year of antiretroviral therapy

| Baseline characteristics | Number (%) 278(100%) | Virological failure | Adjusted odds ratio (95%, Confidence interval) | P-Value |
|-------------------------|------------------------|---------------------|-----------------------------------------------|---------|
| Age                     |                        |                     |                                               |         |
| 2-5 Years               | 51(18%)                | 14(27%)             | 1.802(0.634-5.127)                            | 0.269   |
| 6-9 Years               | 119(43%)               | 36(30%)             | 1.033(0.462-2.307)                            | 0.937   |
| Gender                  |                        |                     |                                               |         |
| Female                  | 146(53%)               | 42(29%)             | 1.614(0.776-3.356)                            | 0.202   |
| Male                    | 132(47%)               | 46(35%)             | 0.170(0.11-2.568)                             | 0.201   |
| Baseline CD4 cells/mm³  |                        |                     |                                               |         |
| <50                     | 8(3%)                  | 2(25%)              | 0.185(0.08-5.1225)                            | 0.81    |
| 50-100                  | 7(3%)                  | 3(43%)              | 4.007(0.399-4.273)                            | 0.24    |
| 101-249                 | 22(8%)                 | 4(18%)              | 0.215(0.064-0.727)                            | 0.013*  |
| 250-349                 | 16(6%)                 | 6(38%)              | 1.046(0.250-4.525)                            | 0.933   |
| CD4 percentage          |                        |                     |                                               |         |
| >25                     | 172(62%)               | 50(29%)             | 1.390(0.459-4.212)                            | 0.561   |
| 15-25                   | 56(20%)                | 23(14%)             | 1.420(0.571-3.528)                            | 0.451   |
| Baseline VL copies/ml   |                        |                     |                                               |         |
| <5000                   | 145(52%)               | 66(46%)             | 7.476(2.34-19.050)                            | 0.001*  |
| 5000-5000               | 25(9%)                 | 6(24%)              | 2.646(0.653-10.721)                           | 0.173   |
| >400 - <1000            | 21(8%)                 | 12(57%)             | 2.375(0.674-8.368)                            | 0.178   |
| Who stage               |                        |                     |                                               |         |
| Stage 1                 | 98(35%)                | 23(23%)             | 0.934(0.131-6.638)                            | 0.946   |
| Stage 2                 | 44(16%)                | 28(64%)             | 1.014(0.137-7.500)                            | 0.989   |
| Stage 3                 | 127(46%)               | 57(45%)             | 0.612(0.88-4.256)                             | 0.621   |
| TB at baseline          |                        |                     |                                               |         |
| Yes                     | 8(3%)                  | 5(63%)              | 0.392(0.125-1231)                             | 0.109   |
| Haemoglobin g/dl        |                        |                     |                                               |         |
| ≤10                     | 123(44.2%)             | 37(30%)             | 1.202(0.578-2.503)                            | 0.622   |
| WBC count               |                        |                     |                                               |         |
| ≤800 ×10³/L             | 28(10%)                | 8(29%)              | 0.691(0.204-2.339)                            | 0.622   |
| Weight for age (WAZ)    |                        |                     |                                               |         |
| Malnourished            | 171(62%)               | 51(30%)             | 1.295(4.10-4.092)                             | 0.661   |
| Normal                  | 74(27%)                | 23(8.2%)            | 0.998(0.274-3.633)                            | 0.997   |
| Adherence at one year   |                        |                     |                                               |         |
| <95%                    | 75(27%)                | 25(38%)             | 151(1.20-3.01)                                | 0.001*  |
| Caretaker education     |                        |                     |                                               |         |
| No education            | 20(7%)                 | 9(45%)              | 1.25(0.44-70.12)                              | 0.79    |
| Primary                 | 170(61%)               | 30(18%)             | 1.80(1.06-3.01)                               | 0.19    |
| Secondary               | 58(21%)                | 35(60%)             | 2.40(1.32-2.40)                               | 0.06    |
| Disclosure (yes)        | 38(14%)                | 18(47%)             | 1.90(0.30-9.78)                               | 0.703   |
Table 6: Factors associated with immunological failure (CD4 <100 cells/mm$^3$) at one year of antiretroviral therapy

| Baseline patient Characteristics | Number (%) | Immunological failure CD4 <100 cells/mm$^3$ at one year | Adjusted odds ratio (95%, confidence interval) | P-value |
|---------------------------------|------------|--------------------------------------------------------|-----------------------------------------------|---------|
| Age                             | 278(100%)  | 1(2%)                                                   | 1.161(0.71-19.109)                           | 0.917   |
| 2-5 years                       | 51(18%)    | 1(2%)                                                   | 5.393(0.84-34.534)                           | 0.075   |
| 6-9 years                       | 119(43%)   | 1(8%)                                                   | 0.803(0.172-3.751)                           | 0.781   |
| Gender                          |            |                                                         |                                               |         |
| Female                          | 146(53%)   | 5(7%)                                                   | 0.284(0.41-1.973)                            | 0.284   |
| Baseline CD4 cells/mm$^3$       |            |                                                         |                                               |         |
| <50                             | 8(3%)      | 2(25%)                                                  | 79.966(4.157-1499.987)                        | 0.004*  |
| 50-100                          | 7(3%)      | 1(33%)                                                  | 166.569(11.865-2538.352)                      | 0.001*  |
| 101-249                         | 22(8%)     | 2(9%)                                                   | 17.25(2.055-1455.388)                         | 0.009*  |
| 250-349                         | 16(6%)     | 3(15%)                                                  | 22.22(1.814-272.418)                         | 0.016*  |
| CD4 percentage                  |            |                                                         |                                               |         |
| >25                             | 172(62%)   | 9(5%)                                                   | 0.277(0.005-5.10)                            | 0.476   |
| 15-25                           | 56(20%)    | 2(4%)                                                   | 0.329(0.06-5.20)                             | 0.239   |
| Baseline VL copies/mm$^3$       |            |                                                         |                                               |         |
| >5000                           | 145(52%)   | 11(8%)                                                  | 0.317(0.26-9.404)                            | 0.369   |
| 1000-5000                       | 25(9%)     | 1(4%)                                                   | 0.527(0.33-8.338)                            | 0.649   |
| >400 - <1000                    | 21(8%)     | 19(90%)                                                 | 1.327(0.77-22.833)                           | 0.846   |
| Who stage                       |            |                                                         |                                               |         |
| Stage 1                         | 98(35%)    | 8(8%)                                                   | 0.98(0.003-3.626)                            | 0.207   |
| Stage 2                         | 44(16%)    | 1(2%)                                                   | 0.289(0.008-6.56)                            | 0.481   |
| Stage 3                         | 127(46%)   | 5(4%)                                                   | 0.277(0.008-9.452)                           | 0.476   |
| TB at Baseline                  |            |                                                         |                                               |         |
| Yes                             | 8(3%)      | 4(50%)                                                  | 0.415(0.95-3.17)                             | 0.397   |
| Haemoglobin g/dl                |            |                                                         |                                               |         |
| ≤10                              | 129(44.2%) | 7(6%)                                                   | 1.201(0.23-6.15)                             | 0.826   |
| ≤0.00 x 10^9/L                   | 28(10%)    | 3(11%)                                                  | 0.327(0.016-6.37)                            | 0.568   |
| Adherence                       |            |                                                         |                                               |         |
| <95%                            | 75(27%)    | 24(32%)                                                 | 1.96(1.09-3.51)                              | 0.004*  |
| Weight for age (WAZ)            |            |                                                         |                                               |         |
| Malnourished                     | 171(62%)   | 9(5%)                                                   | 0.543(0.26-1.047)                            | 0.584   |
| Normal                           | 74(27%)    | 3(4%)                                                   | 0.358(0.19-0.54)                             | 0.43    |

*p ≤0.05 is statistically significant

Table 7: Factors associated with immunological failure (CD4 <15%) at one year of antiretroviral therapy

| Baseline patient Characteristics | Number (%) | Immunological failure CD4 <15% | Adjusted odds ratio (95%, confidence interval) | P-value |
|---------------------------------|------------|--------------------------------|-----------------------------------------------|---------|
| Age                             | 278(100%)  | 6(12%)                         | 1.269(0.356-4.525)                             | 0.713   |
| 2-5 years                       | 51(18%)    | 6(12%)                         | 1.459(0.560-3.801)                             | 0.439   |
| 6-9 years                       | 119(43%)   | 17(14%)                        | 0.579(0.241-1.392)                             | 0.222   |
| Gender                          |            |                                |                                               |         |
| Female                          | 146(53%)   | 15(10%)                        | 1.321(0.880-19.787)                            | 0.841   |
| Male                            | 132(47%)   | 21(16%)                        | 0.579(0.241-1.392)                             | 0.222   |
| Baseline CD4 cells/mm$^3$       |            |                                |                                               |         |
| <50                             | 8(3%)      | 2(25%)                         | 0.402(0.491-3.009)                             | 0.194   |
| 50-100                          | 7(3%)      | 3(43%)                         | 15.962(1.696-150.255)                          | 0.015   |
| 101-249                         | 22(8%)     | 4(18%)                         | 1.849(0.397-8.608)                             | 0.434   |
| 250-349                         | 16(6%)     | 3(19)                          | 2.227(0.010-1.569)                             | 0.356   |
| CD4 percentage                  |            |                                |                                               |         |
| >25                             | 172(62%)   | 20(12%)                        | 0.397(0.0101-1.569)                            | 0.188   |
| 15-25                           | 56(20%)    | 10(18%)                        | 0.743(0.272-2.027)                             | 0.562   |
| Baseline VL copies/ml           |            |                                |                                               |         |
| >5000                           | 145(52%)   | 24(17%)                        | 0.420(0.134-1.310)                             | 0.135   |
| 1000-5000                       | 25(9%)     | 2(8%)                          | 1.965(0.46-9.480)                              | 0.401   |
| >400 - <1000                    | 21(8%)     | 19(90%)                        | 0.547(0.88-3.403)                              | 0.517   |
| Who stage                       |            |                                |                                               |         |
| Stage 1                         | 98(35%)    | 1(1%)                          | 0.019(0.001-0.268)                             | 0.003   |
| Stage 2                         | 44(16%)    | 8(18%)                         | 0.673(0.101-4.483)                             | 0.693   |
| Stage 3                         | 127(46%)   | 7(6%)                          | 0.677(0.104-4.21)                              | 0.684   |
| TB AT baseline                  |            |                                |                                               |         |
| YES                             | 8(3%)      | 7(88%)                         | 0.331(0.097-1.124)                             | 0.076   |
| Haemoglobin g/dl                |            |                                |                                               |         |
| ≤10                              | 123(44.2%) | 14(11%)                        | 0.792(0.307-2.046)                             | 0.631   |
| WBC count                       |            |                                |                                               |         |
| ≤0.00 x 10^9/L                   | 28(10%)    | 4(14%)                         | 0.672(0.139-3.263)                             | 0.622   |
| Weight for age (WAZ)            |            |                                |                                               |         |
| Malnourished                     | 171(62%)   | 23(13%)                        | 1.381(0.324-5.887)                             | 0.662   |
| Normal                           | 74(27%)    | 10(14%)                        | 1.808(0.353-9.169)                             | 0.479   |

*p ≤0.05 is statistically significant
Discussion

The use of a potent combination of antiretroviral drugs has led to reductions in the morbidity and mortality associated with human immunodeficiency virus (HIV)-1 infection. Antiretroviral therapy can reverse HIV-related growth failure with a significant reduction in HIV-related morbidity and mortality. In this retrospective study we report immune-virological outcomes in paediatric patients receiving antiretroviral agents for 2 years. The median age at antiretroviral therapy initiation in this study was 8 years. Early antiretroviral initiation is recommended in all children aged <5 years before growth failure and severe immunosuppression sets in and this prevents growth failure and opportunistic infections. 

After one year of antiretroviral therapy, 36% of the children had virological failure (viral load > 400 copies/mL). Five percent (CD4 count <100 cells/mm³) and thirteen percent (CD4 count < 100 cell /mm³) of the children failed immunologically. Previous reports indicate that within two years of first-line ART initiation, 33-38% of children experience virological failure and those on NNRTI-based regimens, have shown lower (19-20%) rates of virological failure at 12 months. These findings are also similar to results of a meta-analyses on VL suppression on NNRTI-based first-line ART in children (60%–70%) in low- and middle-income countries. Different limits of quantification and variations in definitions of virological failure as a VL of 400, 1000 or 5000 copies/ml at one or two repeated visits in different studies may be responsible for different rates observed in literature. Failure to achieve virological suppression may be due to the presence of HIV species resistant to antiretroviral drugs including maternally transmitted resistant strains or inadequate adherence, amongst other factors.

Virological failure was significantly more common in patients with baseline viral load >5000 copies/ml, low baseline CD4 count and poor adherence. This finding is consistent with earlier observations which suggest that infants and young children often present high viral load and that it will take longer to fully suppress viral replication. Surprisingly, non-disclosure of the child’s status was not associated with virological failure. Disclosure of the child’s HIV status should be done when the child is old enough to understand the information and this should be accompanied by appropriate health education and counselling to ensure a positive impact on adherence to therapy and treatment outcomes. Other factors such as weight and gender were not significant in this study. Limited paediatric data suggest that underlying malnutrition may not adversely affect immunologic and virologic response to antiretroviral therapy. In addition to sustained adherence which results in optimal therapeutic drug levels, several factors including gender of the child, lower CD4 counts, longer duration on antiretroviral therapy, genetic variants, co-infection with tuberculosis and lower baseline weight have all been demonstrated to affect virological suppression.

Viral blips (temporary, detectable increase in the amount of HIV in the blood (viral load) that occurs after antiretroviral therapy (ART) has effectively suppressed the virus to an undetectable level) and rebound (persistent, detectable levels of HIV in the blood after a period of undetectable levels) has been associated with a poorer clinical outcome. In this study, 6.1% of patients had virologic blips at 24 months. Several retrospective and prospective studies have demonstrated that blips are common, with the percentage of patients who experience a blip over time ranging from 10% to 40%. Previous reports show that among patients who reach an undetectable viral load in the early course of therapy 20 to 53% have a subsequent virological rebound, i.e. an increase in viral load above the detection. The cause of viral blips and rebound is likely multi-factorial and several contributing factors have been proposed to explain detection of intermittent low-level viral loads. These include emergence of mutant resistant viruses, with detection of persistent or intermittent low-level releases of virus from existing reservoirs, random laboratory variation, laboratory test and operator error, poor and decreased adherence to antiretroviral therapy, immunization or intercurrent illness, and insufficient antiretroviral drugs threshold.

In the present study, virologic blips were higher among subjects with adherence <95% (although not statistically significant), however the association between viral blips and either age, weight, or gender was not significant. There are concerns that measurable virologic blips and rebound viremia may represent an increased risk for subsequent drug resistance and treatment failure. Viraemic rebound has been associated with increased drug resistance and has been shown to occur more often in patients with high baseline HIV RNA and low baseline CD4 cell count (less than 350 cells/mm³). Despite an adequate immunological response, about 30% of patients in this study did not achieve an adequate virologic response. In previous studies, discordant response to therapy occurs in 20 to 40% of treated patients, with isolated immunological response being slightly more common than isolated virologic response.

The mechanisms by which CD4 cell counts are maintained in the face of ongoing viral replication are not known, but they may include decreased viral replication capacity, impaired viral replication in thymic tissue, decreased cell death by activation-induced apoptosis, or regeneration of HIV-specific immune responses. The CD4 absolute count is the most important laboratory indicator of immune function in patients with HIV and is highly variable. CD4 percentage remains stable and may be more appropriate parameters to assess a child’s immune function. The follow up of patients on antiretroviral therapy in various countries without uniform guidelines on clinical, immunological and virological criteria has resulted in early or late switching for second line drugs.

Progression of HIV is faster in children than in adults. Differences between absolute CD4 lymphocyte count and CD4 lymphocyte percentage may represent a type of
immune discordance. A relatively high absolute CD4 lymphocyte count and a low CD4 lymphocyte percentage may occur in 8%-10% of untreated HIV-infected patients. This has potentially important clinical implications. Therefore, some investigators have argued that since the CD4 lymphocyte percentage is directly measured and is less variable over time, it may be a better marker for monitoring patients than the absolute CD4 lymphocyte count. 

In this study, in all age groups there was an improvement in CD4 t-lymphocyte cell indices and during the first year on antiretroviral therapy. The patients had high baseline CD4 counts. Previous studies suggest that HIV patient with high CD4 cell count at the time of ART initiation may be at greater risk of treatment attrition. Patient education and healthcare provider training on the importance of ART adherence in patients with high pre-initiation CD4 counts should be enhanced. The finding that low baseline CD4 counts and poor adherence were significantly associated with immunological failure is supported by several other studies. HIV-infected children who start antiretroviral therapy at lower CD4% reach lower peak CD4 levels perhaps from persistent effects of chronic immune activation. Antiretroviral therapy initiation at younger ages is associated with better immunologic recovery.

It is estimated that 90% of these children would have experienced CD4% recovery to normal within 4 years, and 80% would have had a normal CD4% at 4 years. Biologically, it is expected that relationships between CD4% recovery and age plateau because the thymic potential stabilizes as children approach adult immune maturity. Early diagnosis and treatment for HIV-infected children before they reach a stage of profound immunodeficiency is very important and this finding will guide clinicians in assessing immunologic response to nucleoside reverse transcriptase inhibitor-based antiretroviral in HIV infected children.

**Conclusion**

The treatment outcomes observed in this study were similar to those reported in earlier studies. Immunological restoration and viral suppression can be achieved and sustained after two years of antiretroviral among children in resource-constrained settings. The high rates of virological failure observed despite good adherence to therapy calls for early introduction and switch to 2nd and third line drugs. The clinical relevance of the observed virological blips, discordant immunovirological responses, needs further investigations in larger studies. Good adherence and caregiver training needs to be sustained.

**References**

1. United Nations Programme on HIV/AIDS, (UNAIDS) AIDS by numbers 2016.
2. Kawo G, Kalokola F, Fataki M, et al. Prevalence of HIV type 1 infection associated clinical features and mortality among hospitalized children in Dar es Salaam, Tanzania. Scand J Infect Dis 2000; 32(4):357-363.
3. UNAIDS. Epidemiological fact sheet on HIV and AIDS: United Republic of Tanzania.2009.
4. World Health Organization ,Towards universal access: scaling up priority HIV/AIDS Interventions in the health sector progress report. 2009.
5. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. J Int AIDS Soc. 2010;13:31.
6. Davies MA, Moultrie II, Eley B et al. Virologic failure and second line antiretroviral therapy in children in South Africa: the International epidemiologic databases to evaluate AIDS (IeDEA) Southern Africa collaboration. J Acquir Immune Defic Syndr. 2011;56(3):270-278.
7. Nitta K, Romance C, Thira S, Khuncha S. Incidence and risk factors of antiretroviral treatment failure in treatment-naive HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther.2011;8(42):1-7.
8. Anude CJ, Eze E, Onyegbutulem HC, Charurat M, Etiebet M, Ajayi S, DAkun P, Akinwande O, Beyrer C, Abimiku A and Blattner W. Immune-virologic outcomes and immunovirologic discordance among adults alive and on antiretroviral therapy at 12 months in Nigeria. BMC Infectious Diseases. 2013;13:113.
9. Brown BJ, Oladokun RE, Odiabo GN, Olaleye DO, Osinusi K and Kanki P. Clinical and immunological Profile of Pediatric HIV Infections in Ibadan, Nigeria J Internatinal Association of Physicians in AIDS Care (JIAPAC), 2011.
10. Ojeniran MA, Emokpaee A, Mabogunje C, Akintan P, Hoshen M and Wesis R. How are children with HIV faring in Nigeria? – a 7 year retrospective study of children enrolled in HIV care BMC Pediatrics. 2015;15:87.
11. Ogbonso BO, Oladokun RE, brown JB, Osinusi KI . Prevalence and clinical pattern of paediatric HIV infection at the University College Hospital, Ibadan, Nigeria: a prospective cross-sectional study. Ital J Pediatr. 2011; 37:29.
12. Federal Ministry of Health Nigeria. Integrated National Guidelines for HIV Prevention, Treatment and Care. Health Workers Desk Reference 2014.
13. Boender TS, Hoenderboom BM, Sianloft KCE, Hamers RL, Wellington M, Shamu T, Siwale M, Maksimos EEF, Nankya I, Kityo CM, Adeyeo TA, Akamanu AS, Botes ME, Ondoap R, Rinke de Wit F. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Clin Infect Dis. 2015; 61 (11): 1749-1758.

14. George Gachara, Lufuno G. Mavhangu, Elizabeth T. Rogowski, Cecile Manhacve, and Pascal O. Bessong. Evaluating Adherence to Antiretroviral Therapy Using Pharmacy Refill Records in a Rural Treatment Site in South Africa. AIDS Research and Treatment 2017; Article ID 5456219. http://dx.doi.org/10.1155/2017/5456219

15. World Health Organization. Antiretroviral Therapy for HIV Infection in Infants and Children: Recommendations for Public Health Approach 2010. In http://www.who.int/hiv/pub/paediatric/infants/en/index.html

16. Chi BH, Cantrell RA, Zulu I et al., "Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia," Intl J of Epidemiol. 2009; 38(3): 746-756.

17. Aurpibul L, Puthanakit T, Taecharoensuk S, Sirisanthana T. Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. AIDS Patient Care STDs. 2009;23(12):1067–71.

18. World Health Organization. The WHO Child Growth Standards, 2013. Available at http://www.who.int/childgrowth/en

19. Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane database Syst Rev (Online). 2012;7:CD004772.

20. Duong T, Judd A, Collins II, Doeholt K, Lyall H, Foster C, et al. Long –term Virological Outcomes in HIV-infected children on ART in UK/Ireland. AIDS . 2014. 28(16):2395-205.

21. Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoeplerman AI, Geelen SP. Long-term Outcome of children receiving antiretroviral treatment in rural south Africa: substantial virologic failure of first-line treatment. Pediatric infect Dis J. 2011; 30(1):52-6.

22. Wamalwa DC, Lehman DA, Benki-Nugent S, Gasper MA, Gichoii R, Maleche-Obimbo E, et al. Long-term virologic response and and genotypic resistance mutations I HIV-1-infected Kenyan children on combination antiretroviral therapy. J Acquir Immune Defic Syndr . 2013; 62(3):267-74.

23. Guidelines for the Use of Antiretroviral Agents in HIV-1- Infected Adults and Adolescents. Office of AIDS Research, NIH—A Working Group of the OARAC. (2008.)

24. El-Khatib Z Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a crosssectional study in Soweto, South Africa. AIDS . 2010; 24: 1679-1687. 92.

25. Le Moing V, Chène G, Masquelier B. et al. 2000. Definition of virological response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy. J Acquir Immune Defic Syndr. 2000; 24: 82-83.

26. Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoap P, Wellington M, Siwale M, Nankya I, Kaudha E, Akamanu AS, Botes ME, Steegen K, Calis JCJ, Rinke de Wit TF and Sigaloff KCE. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother 2016; 71: 2918-2927.

27. Van Rossum AMC, Fraaij PLA, De Groot R. Efficacy of highly active antiretroviral Therapy in HIV-infected children. The Lancet Infect Dis. 2002; 2:93-102.

28. Ahoua L, Guenther G, Pinoles A, Anguza P, Chai XL, Le Tiec C, Balkan S, Olson D, Olaroc P, Pujades-Rodriguez M. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009.; 9 (81)-11

29. Mellors W, Rinaldo CR, Gupta P, White RM, Todd JM, Kingsley LA. Prognosis in HIV-1 infection predicted in the quantity of virus in plasma . Sciences 1996 ;272: 1167 -1170

30. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, Francioli P, Furrer H, Battegay M, Vernazza P, Bernasconi E, Gunthard HF, Hirschel B, Phillips AN, Telenti A Frankfurt HIV Clinic Cohort and Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. 2002 ; AIDS 16 (14):1967–1969.

31. Di Mascio M, Markowitz M, Louie M, Hogan C, Hurley A, Chung C, Ho D, Perelson AS. Viral blip dynamics during highly active antiretroviral therapy. J Virology. 2003; 77 (22): 12165–12172.

32. Khan MA. Blips and its clinical relevance in HIV Paients on Treatment Intl J Collab Res Intern Med & Public Health. 2012; 4:6:934.

33. Macias J, Palomares JC, Mira JA, Torres MJ, Garcia Garcia JA, Rodriguez JM, Vergera S, Pineda JA. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infections 2005 ; 51(3):195-200
34. Grabar S, Pradier C, Le Corfec E, Lancer R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro –peray P, Poizot-Martin I, Costagliola D. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. Acquired Immune Deficiency Syndrome. 2000; 14(2):141-149.

35. Moore RD, Keruly JC. CD4 cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44 (3):441–446.

36. Cohen JW, Slieker WA, Rijkers GT, Noest A, Boucher CA, Suur MH, de Boer R, Geelen SP, Scherbier HJ, Hartwig NG, Hooijkaas H, Roos MT, de Graeff Meeder B, de Groof R. Early recovery of CD4+ lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections. Acquired Immunodeficiency Syndrome 1998;12(16):2155-2159.

37. Hulgan T, Raffanti S, Kheshti A, Blackwell RB, Rebeiro PF, Barkanic G, Ritz B, Sterling TR. CD4 lymphocyte percentage predicts disease progression in HIV infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts 1350 CD4 lymphocytes/mm^3. J Infect Dis. 2005; 192 (6):950-957.

38. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis. 1994;169(1):28-36.

39. Buchanan AM, Cunningham CK. Advances and failures in preventing perinatal human immunodeficiency virus infection. Clin Microbiol Rev. 2009;22(3):493-507.

40. Fox MP, Shearer K, Maskew M, Meyer-Rath G, Clouse K, Sane I. Attrition through Multiple Stage of Pre-Treatment and ART HIV Care in South Africa. PloS One. 2014; 9:e110252.

41. Tang Z, Stephen W, Pan, Yuhua Ruan, Xuanhua Liu, Jinning Su, Qiuying Zhu, Zhiyong Shen, Hen Zha ng, Yi Chen, Guagbua Lan, Hui Xing, Lingjie Liao, Yi Feng & Yiming, Shao. Effects of high CD4 cell counts on death and attrition among HIV patients receiving antiretroviral treatment: an observational cohort study. Scientific Reports. 2017; 7 :3139.

42. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4 T-cell response to highly active antiretroviral therapy according to baseline CD4 T-cell count. J Acquir Immune Defic Syndr. 2004;36:702-713.

43. Kaufmann GR, Bloch M, Finlayson R, Zauders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS. 2002;16(3):359-367.

44. Newell ML, Patel D, Goethe-buer T, Thorne C; European Collaborative Study. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection:is it associated with age at initiation? J Infect Dis. 2006;193 (7):954-962.

45. Weinberg A, Dickover R, Britto P, Hu C, Patterson – Brrtlett J, Kraismer J, Gutzman H, Shearer WT, Rathore M, Mckinney R, PACTG 1021 Team . Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. Acquired Immune Deficiency Syndrome. 2008; 22(17):2267-2277.

46. Soh CH, Oleske JM, Brady MT, Spector SA, Borkowsky W, Burchett SK, Foca MD, Handesman E, Jimenez E, Dankner WM, Hughes MD, Paediatric AIDS Clinical Trials Group . Long-term effects of protease inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003;362 (9401), 2045-2051.